In the European pharmaceutical industry, there were 26 private equity deals announced in Q2 2023, worth a total value of $380.8m, according to GlobalData’s Deals Database. The $271.4m investment by montana capital partners in sanecum group was the industry’s largest disclosed deal. A thorough analysis of the disruptive themes, the M&A activity and most notable deals are included in GlobalData’s Pharma Industry Mergers and Acquisitions Deals by Top Themes report. Buy the report here.
In value terms, private equity deal activity in Europe decreased by 90% in Q2 2023 compared with the previous quarter’s total of $3.8bn and rose by 69% as compared to Q2 2022. Related deal volume increased by 63% in Q2 2023 versus the previous quarter and was 53% higher than in Q2 2022.
The top-ranked financial advisors supporting these private equity deals in Europe in Q2 2023 were Deloitte NSE; Rothschild & Co; Alvarez & Marsal Holdings with 3, 3, 2 deals respectively.
The top-ranked legal advisors supporting these private equity deals in Europe Q2 2023 were Baker & McKenzie; CMS Legal Services EEIG; Macfarlanes with 3, 2, 2 deals respectively.
For further understanding of GlobalData's Pharma Industry Mergers and Acquisitions Deals by Top Themes, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
Smarter leaders trust GlobalData
Premium Insights Pharma Industry Mergers and Acquisitions Deals by Top Themes in 2022 - Thematic Intelligence
Premium Insights
The gold standard of business intelligence.
